Gilgamesh Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy. Mental health worldwide has reached epidemic proportions and novel treatments have not kept pace with the urgent need to treat depression, anxiety, drug addiction and many other devastating diseases. Our purpose is to accelerate treatments and fundamentally improve mental health.
Gilgamesh Pharmaceuticals has raised $80.1M across 4 funding rounds on record, the most recent a Series A of $60.0M announced in Mar 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Gilgamesh Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Gilgamesh Pharmaceuticals Funding Rounds
1 of 4 rounds was announced without a disclosed amount and is excluded from the total.
Gilgamesh Pharmaceuticals announced an undisclosed round in Nov 2022; the amount was not disclosed.
1.3 years later, an undisclosed round of $14.0M was announced in Mar 2024.
1.9 years later, an undisclosed round of $6.1M was announced in Feb 2026.
1 month later, a Series A of $60.0M was announced in Mar 2026.
Gilgamesh Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Gilgamesh Pharmaceuticals Funding Compared to Other Biotechnology Startups
Gilgamesh Pharmaceuticals' latest round of $60.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Gilgamesh Pharmaceuticals in Biotechnology and New York
Companies Similar to Gilgamesh Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Gilgamesh Pharmaceuticals Funding FAQs
What does Gilgamesh Pharmaceuticals do?
Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy. Mental health worldwide has reached epidemic proportions and novel treatments have not kept pace with the urgent need to treat depression, anxiety, drug addiction and many other devastating diseases. Our purpose is to accelerate treatments and fundamentally improve mental health.
How much funding has Gilgamesh Pharmaceuticals raised?
Gilgamesh Pharmaceuticals has raised $80.1M across 4 rounds on record. The most recent is a Series A of $60.0M announced in Mar 2026.
When did Gilgamesh Pharmaceuticals last raise funding?
Gilgamesh Pharmaceuticals' most recent funding round on record is a Series A of $60.0M, announced in Mar 2026.
Who founded Gilgamesh Pharmaceuticals?
FundedIQ lists Dalibor Sames (Founder), Jonathan Sporn (Founder) at Gilgamesh Pharmaceuticals.
Where is Gilgamesh Pharmaceuticals headquartered?
Gilgamesh Pharmaceuticals is based in New York, United States.
How many employees does Gilgamesh Pharmaceuticals have?
Gilgamesh Pharmaceuticals is in the 11-50 employee band.
How does Gilgamesh Pharmaceuticals' funding compare to other Biotechnology startups?
Gilgamesh Pharmaceuticals' latest round of $60.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Gilgamesh Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Gilgamesh Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.